1-3 of 3
Per Andersson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Correlation between Duration of Concomitant Exposure to Acid Reduction Agents and Remission Rates in Newly Diagnosed CML Patients on TKI's

Free
Adrian Kilcyone, Pierantonio Russo, Charlotta Liljebris, Ramaa Nathan, Carlton Anderson, Michael Sicilia, Alex Moore, Sudarshan Prasad, Per Andersson
Journal: Blood
Blood (2024) 144 (Supplement 1): 6606.
https://doi.org/10.1182/blood-2024-209909
Published: 2024
Journal Articles

XS004 Dasatinib (XS004) Improves Variability and Bioavailability in Humans Using Amorphous Solid Dispersion Formulation of Dasatinib with Potential Implications for Its Clinical Use

Free
Hans Lennernäs, Charlotta Liljebris, Magnus Brisander, Gérald Jesson, Per Andersson, Gunnar Larfors, Leif Stenke
Journal: Blood
Blood (2022) 140 (Supplement 1): 9652–9653.
https://doi.org/10.1182/blood-2022-169884
Published: 2022
Journal Articles

Comedication of Proton Pump Inhibitors and Dasatinib Is Common in CML but XS004, a Novel Amorphous Solid Dispersion Formulation of Dasatinib, Provides Improved Uptake and Low pH-Dependency, Minimizing Unwanted Drug-Drug Interactions

Free
Gunnar Larfors, Hans Lennernäs, Charlotta Liljebris, Magnus Brisander, Gérald Jesson, Per Andersson, Leif Stenke
Journal: Blood
Blood (2022) 140 (Supplement 1): 6769–6770.
https://doi.org/10.1182/blood-2022-156487
Published: 2022